DE69619683T2 - Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv - Google Patents

Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv

Info

Publication number
DE69619683T2
DE69619683T2 DE69619683T DE69619683T DE69619683T2 DE 69619683 T2 DE69619683 T2 DE 69619683T2 DE 69619683 T DE69619683 T DE 69619683T DE 69619683 T DE69619683 T DE 69619683T DE 69619683 T2 DE69619683 T2 DE 69619683T2
Authority
DE
Germany
Prior art keywords
human breast
mmtv
wap
regulatory sequences
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69619683T
Other languages
English (en)
Other versions
DE69619683D1 (de
Inventor
H Guenzburg
Michael Saller
Brian Salmons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschung De
Original Assignee
AUSTRIAN NORDIC BIOTHERAPEUTIC
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AUSTRIAN NORDIC BIOTHERAPEUTIC, Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical AUSTRIAN NORDIC BIOTHERAPEUTIC
Publication of DE69619683D1 publication Critical patent/DE69619683D1/de
Application granted granted Critical
Publication of DE69619683T2 publication Critical patent/DE69619683T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C12N9/0038—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6) with a heme protein as acceptor (1.6.2)
    • C12N9/0042—NADPH-cytochrome P450 reductase (1.6.2.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE69619683T 1995-09-06 1996-09-06 Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv Expired - Lifetime DE69619683T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK97695 1995-09-06
PCT/EP1996/003922 WO1997009440A1 (en) 1995-09-06 1996-09-06 The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells

Publications (2)

Publication Number Publication Date
DE69619683D1 DE69619683D1 (de) 2002-04-11
DE69619683T2 true DE69619683T2 (de) 2002-09-26

Family

ID=8099620

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69619683T Expired - Lifetime DE69619683T2 (de) 1995-09-06 1996-09-06 Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv

Country Status (9)

Country Link
US (1) US20050019307A1 (de)
EP (1) EP0848757B1 (de)
JP (1) JPH11511979A (de)
AT (1) ATE214101T1 (de)
AU (1) AU6987696A (de)
DE (1) DE69619683T2 (de)
DK (1) DK0848757T3 (de)
ES (1) ES2174103T3 (de)
WO (1) WO1997009440A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0817858T3 (da) 1995-03-09 2003-08-11 Gsf Forschungszentrum Umwelt Vektorer, som indeholder terapeutiske gener for antimikrobielle peptider, til anvendelse ved genterapi
PL185338B1 (pl) 1995-06-27 2003-04-30 Bavarian Nordic As Kapsułka otaczająca linię komórek pakujących produkujących cząsteczki retrowirusa, sposób otrzymywania kapsułki otaczającej linię komórek pakujących produkujących cząsteczki retrowirusa, zastosowanie kapsułki otaczającej linię komórek pakujących produkujących cząsteczki retrowirusa, sposób wytwarzania kompozycji farmaceutycznej oraz kompozycja farmaceutyczna
US7074398B1 (en) 1995-10-13 2006-07-11 Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences
CA2250173A1 (en) * 1996-03-27 1997-10-02 Bavarian Nordic Research Institute Cytochrome p450 transducing retroviral vectors
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
WO1999035280A1 (en) 1998-01-06 1999-07-15 Bavarian Nordic Research Institute A/S Reconstituting retroviral vector (recon vector) for targeted gene expression
DE19903371C1 (de) * 1999-01-28 2000-06-15 Mice & More Gmbh & Co Kg Säugetier sowie Verfahren zu seiner Herstellung und seine Verwendung
ES2443416T3 (es) * 2002-07-18 2014-02-19 Helix Biopharma Corp. Uso de ureasa para inhibir el crecimiento de células cancerosas
CN101955523B (zh) * 2010-03-10 2014-06-25 中国科学院海洋研究所 一种具抑菌活性的中华绒螯蟹乳清酸蛋白的制备及应用
CA3057549A1 (en) * 2017-03-21 2018-09-27 PharmaCyte Biotech, Inc. Encapsulated cells producing cytochrome p450 and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873316A (en) * 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5997859A (en) * 1988-03-21 1999-12-07 Chiron Corporation Method for treating a metastatic carcinoma using a conditionally lethal gene
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
WO1995015334A1 (en) * 1993-11-30 1995-06-08 California Pacific Medical Center Research Institute cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT

Also Published As

Publication number Publication date
WO1997009440A1 (en) 1997-03-13
DK0848757T3 (da) 2002-07-01
EP0848757A1 (de) 1998-06-24
ES2174103T3 (es) 2002-11-01
DE69619683D1 (de) 2002-04-11
AU6987696A (en) 1997-03-27
US20050019307A1 (en) 2005-01-27
EP0848757B1 (de) 2002-03-06
ATE214101T1 (de) 2002-03-15
JPH11511979A (ja) 1999-10-19

Similar Documents

Publication Publication Date Title
DE69839815D1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
ATE354372T1 (de) Verwendung von mif-antagonisten zur krebstherapie
DE69619683D1 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
DE69534180D1 (de) Promotor der tie rezeptor protein kinase
DE59510466D1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DK0574394T3 (da) I den humane terapi anvendelige stoffer af polypeptidnatur
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
DE69827805D1 (de) Verfahren und vorrichtung zur bestimmung des transformationspotentials von verbindungen.
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
DE69712182D1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
DE69803052T2 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
ATE265526T1 (de) Genetisch veränderte fibroblasten und ihre verwendung
DE60034434D1 (de) Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
DE60040910D1 (de) Inaktivierte zytokine zur immunisierung
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GSF - FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT

8327 Change in the person/name/address of the patent owner

Owner name: HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNG, DE